OFFICE-CJT
22.12.2020 01:32:09 CET | Business Wire | Press release
Seven international musicians held a live-streaming concert on September 30, 2020, at Absolute Blue in Ikebukuro, Tokyo, featuring progressive jazz music mixed with traditional Japanese sounds.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201221005264/en/
YOUTUBE: https://www.youtube.com/watch?v=BjAHU1IfLh8
The concert was hosted by Creative Jazz Trio with four guest performers. Since 2014, the trio has been actively performing a unique blend of classic and jazz music.
The guest performers included University of Science and Arts of Chiapas (UNICACH) Junior Professor Keiko Kotoku, the youngest soloist winner of second prize in the Universal Marimba Competition 2013 in Belgium. She also won first prize in Duo category in the same competition.
Among other international guest musicians were traditional Japanese Gagaku artists Motonori Miura (hichiriki) and Fumiya Otonashi (shō). They have toured worldwide with Tim Hecker, a world-renowned electronic music artist. They also perform in Hecker’s albums “Konoyo” (2018) and “Anoyo” (2019).
The special unit for the concert was named “CJT+Japonism,” reflecting the artists’ intentions to create music that embodies how Japan is viewed from the world. This concert was actually a rare blessing amid the health crisis, as the performers—usually busy performing around the globe—were confined in Japan due to the outbreak of COVID-19.
The live-streaming featured 9 songs written by Takafumi Kakizaki, composer and drummer of Creative Jazz Trio. The YouTube highlight video includes a full 22-minute performance of “Samsara - Rinnetenshō -”, a song themed on Zen, a school of thoughts on life and death, in which every instrument steals the limelight. Performer interviews are also featured in the video.
The leader of the band, Takafumi Kakizaki, is trained in modern music composition and percussion. He currently creates and performs music across all genres in Tokyo. His activities include performing in Japan tours with WDR Radio Orchestra Cologne Soloclarinetist Andy Miles and Portuguese trumpet player Gileno Santana, playing as an invited guest in France, and organizing master classes in Mexico.
Mixing traditional Japanese music with modern music had been on Takafumi’s mind, triggering him to form “CJT+Japonism” with musicians he had acquainted from past performances.
The group hopes to organize a world tour after the COVID-19 pandemic subsides. Creation of their studio-recorded album is underway. Stay tuned for more news from the group.
WEBSITE: http://cjt.tkdr.net/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201221005264/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom